Action required: Please refresh your browser
We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.
More details about this topic are available here »
| ImmuncoCellular Therapeutics to Present at the 10th Annual LD Micro Main Event on December 7, 2017 | ||
| By: PR Newswire Association LLC. - 22 Nov 2017 | Back to overview list |
|
LOS ANGELES, Nov. 22, 2017 /PRNewswire/ -- ImmunoCellular Therapeutics, Ltd. ("ImmunoCellular") (NYSE American: IMUC), a biotechnology company developing immunotherapies for the treatment of cancer based on Stem-to-T-Cell research, announced today that Anthony Gringeri, Ph.D., President and Chief Executive Officer, Steven Swanson, Ph.D., Senior Vice President, Research, and David Fractor, Chief Financial Officer, will present at the 10th Annual LD Micro Main Event on Thursday, December 7, 2017 at 9:30 a.m. PT (12:30 p.m. ET) in Track 3. The conference is being held at the Luxe Sunset Boulevard Hotel in Los Angeles, CA. Management will be available for one-on-one meetings on Thursday, December 7, 2017. Investors interested in arranging a meeting with management should contact their LD Micro representative or Lytham Partners at (602) 889-9700 or imuc@lythampartners.com. Interested parties who wish to listen to the webcast of the ImmunoCellular LD Micro presentation should visit the Investor Relations section of ImmunoCellular's website at www.imuc.com, under the Events and Presentations tab. A replay of the webcast will be available one hour after the conclusion of the event. The webcast will contain forward-looking statements. The information provided on the webcast is accurate only at the time of the webcast, and ImmunoCellular will take no responsibility for providing updated information except as required by law. About ImmunoCellular Therapeutics, Ltd. ImmunoCellular Therapeutics, Ltd., based in Los Angeles, is developing immune-based therapies for the treatment of cancer. ImmunoCellular is focused on advancing its Stem-to-T-Cell research program, which engineers hematopoietic stem cells to generate cytotoxic T cells. Additional assets, for which the Company is seeking partners, include clinical-stage programs - ICT-107, ICT-121 and ICT-140 - which are patient-specific, dendritic cell-based immunotherapies targeting solid tumors. To learn more about ImmunoCellular, please visit www.imuc.com. ImmunoCellular Therapeutics, Ltd. Contact: Jane Green Investor Relations Contact: Lytham Partners, LLC
View original content with multimedia:http://www.prnewswire.com/news-releases/immuncocellular-therapeutics-to-present-at-the-10th-annual-ld-micro-main-event-on-december-7-2017-300560205.html SOURCE ImmunoCellular Therapeutics, Ltd. 
|
||
|
||
 | Back to overview list | |